Date:11/8/2010

,030)Provision for income taxes(1)(1)(1)(1)Loss from continuing operations(18,162)(21,214)(56,342)(38,031)Income (loss) from discontinued operations183148(3,212)(3,048)Net loss$
(17,979)$
(21,066)$
(59,554)$
(41,079)Basic and diluted net loss per share:Continuing operations$
(0.22)$
(0.30)$
(0.70)$
(0.55)Discontinued operations0.000.00(0.04)(0.04)Net loss per share$
(0.22)$
(0.30)$
(0.74)$
(0.59)Shares used in per share computation:Basic81,17270,94280,92670,149Diluted82,96673,32480,92670,149VIVUS, Inc.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except par value amount)September 30December 3120102009*(unaudited)Current assets:Cash and cash equivalents$
29,036$
40,533Available-for-sale securities 129,162166,241Inventories, net1,803-Prepaid expenses and other assets2,3063,968Current assets of discontinued operations7,78612,620Total current assets170,093223,362Property and equipment, net240290Non-current assets of discontinued operations5,5956,380Total assets $
75,928$
230,032Current liabilities:Accounts payable$
4,677$
8,082Accrued and other liabilities10,4056,891Current liabilities of discontinued operations5,3307,537Total current liabilities20,41222,510Notes payable-net of current portion15,25515,255Non-current liabilities of discontinued operations5,0685,541Total liabilities40,73543,306Commitments and contingenciesStockholders' equity:Common stock; $.001 par value; shares authorized 200,000;  shares outstanding -81,206 at September 30, 2010;80,607 at December 31, 2009, respectively8181Additional paid-in capital428,703420,708Accumulated other comprehensive income (loss)

23(3)Accumulated deficit (293,614)(234,060)Total stockholders' equity135,193186,726Total liabilities and stockholders' equity$
75,928$
230,032*The Condensed Consolidated Balance Sheet at December 31, 2009 has been derived from the  Company's audited financial statements at that date.
'/>"/>

SOURCE VIVUS, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results